Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation

• Published in: The Journal of heart and lung transplantation Vol. 19; no. 12; pp. 1219 - 1223
• Main Authors: Revell, Matthew P, Lewis, Michael E, Llewellyn-Jones, Carol G, Wilson, Ian C, Bonser, Robert S
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.12.2000; Elsevier Science
• Subjects: Biological and medical sciences; Biopsy; Bronchi - physiopathology; Bronchiolitis Obliterans - drug therapy; Cyclosporine - therapeutic use; Disease Progression; Follow-Up Studies; Forced Expiratory Volume - drug effects; Heart-Lung Transplantation - physiology; Humans; Immunomodulators; Immunosuppressive Agents - therapeutic use; Lung Transplantation - physiology; Maximal Midexpiratory Flow Rate - drug effects; Medical sciences; Pharmacology. Drug treatments; Retrospective Studies; Spirometry; Statistics, Nonparametric; Syndrome; Tacrolimus - therapeutic use; Human; Postoperative; Drug combination; Respiratory disease; Lung; Exploration; Transplantation; Homotransplantation; Immunomodulator; Chemotherapy; Lung function; Treatment; Respiratory failure; Tacrolimus; Surgery; Bronchus disease; Complication; Bronchiolitis obliterans; Ciclosporin
• ISSN: 1053-2498; 1557-3117
• DOI: 10.1016/S1053-2498(00)00206-0

We studied serial lung function in 11 patients with bronchiolitis obliterans syndrome who were treated with tacrolimus conversion following lung or heart–lung transplantation. Our results show that tacrolimus conversion slows the decline of lung function in bronchiolitis obliterans syndrome. The attenuation continues for at least 1 year following conversion.